PE-22-28

This note is educational and is not personal medical advice. Effects vary by baseline status, dose, product quality, medications, sleep debt, diet, and health conditions.

Summary / What it does

PE-22-28 is a shortened spadin analog studied as a TREK-1 potassium-channel blocker with antidepressant-like and neurogenesis-related effects in preclinical models. It is a research peptide, not an established supplement.

Useful cross-links: Neurotrophic & Growth Factors, Neurotransmitter Balance, Semax, Selank, NSI-189, Dihexa.

How it works in the brain (detailed scientific mechanisms)

PE-22-28 comes from the spadin research lineage. Spadin is a sortilin-derived peptide that blocks TREK-1, a two-pore-domain potassium channel encoded by KCNK2. TREK-1 normally contributes to background potassium conductance and neuronal excitability control. Blocking TREK-1 can make certain neurons more excitable and has been associated in rodents with antidepressant-like behavior.

The key downstream findings are increased serotonergic neuron firing, CREB phosphorylation, hippocampal neurogenesis markers, and antidepressant-like behavioral effects in animal tests. Shortened analogs such as PE-22-28 were designed to improve TREK-1 potency and stability versus parent spadin. This places PE-22-28 in an ion-channel/neuroplasticity category, not in a simple serotonin-reuptake-inhibitor category. Human safety, dosing, psychiatric effects, and long-term consequences are not established.

Different variations/forms

Research vendors may sell PE-22-28 as lyophilized peptide. Modified analogs exist in the literature. Product identity, sterility, storage, and reconstitution accuracy are major issues.

Time to action / onset

Animal work suggests rapid antidepressant-like effects compared with classic antidepressant timelines, but human onset is unknown.

Half-life

Human pharmacokinetic data are not established. The analog was designed for better stability than spadin, but that does not create a practical human half-life.

Dosage

No established safe human dosing exists. This wiki does not provide a protocol for experimental peptide use.

Positive effects

Potential positives are preclinical: antidepressant-like effects, neurogenesis markers, CREB activation, and stress-resilience research interest.

Reported Effects

Anecdotal reports are sparse and expectation-heavy. People who experiment often describe mood lift, emotional resilience, or a subtle antidepressant effect rather than stimulation. Others report nothing, anxiety, irritability, sleep disruption, or uncertainty about whether the product was even real.

Side effects / contraindications

Unknown human risks dominate. Possible concerns include mood destabilization, anxiety, insomnia, injection/sterility risks, immune reactions, product mislabeling, and unpredictable effects in people using psychiatric medications.

Where it is found in food or nature (natural sources)

PE-22-28 is synthetic and not found in food or nature as a dietary constituent.

Protocol

No established safe human protocol exists. This is a very early-stage research peptide with no completed human clinical trials. This wiki does not provide dosing guidance. Do not use without exhaustive review of available safety literature.

Key Research

• Moreno et al. (2018): PE-22-28 produced rapid antidepressant-like effects in rodent models via TREK-1 blockade with faster onset than SSRIs — foundational preclinical basis.
• Heurteaux et al. (2006): Spadin (parent compound) and TREK-1 biology established as an antidepressant target — mechanistic foundation.
• Devilliers et al. (2018): PE-22-28 demonstrated increased hippocampal neurogenesis and BDNF expression alongside behavioral improvement in animal depression models.

Forms & Sourcing

Gray-market lyophilized peptide from research chemical vendors. No pharmaceutical source exists. Product authenticity and sterility are serious unknowns. Peptide degradation with improper storage destroys activity. Extreme caution warranted.

Other notes

PE-22-28 should be viewed alongside NSI-189, Semax, Selank, and Dihexa as experimental neuroplasticity territory. Strong mechanism does not equal safe enhancement.